E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Pharma-50-transparent_216px_red

Become a Fan

« NRT Technology Corp. v. Everi Payments, Inc. (PTAB 2016) | Main | Verint Systems Inc. v. Red Box Recorders Ltd. (S.D.N.Y. 2016) »

December 12, 2016

Comments

Hey Kevin,

Nice write up on the SG's recommendation to SCOTUS grant cert. And you correctly point out the problems with the SG's spin on how this biosimilars law should be interpreted. R&D expenditures on drugs, like money, doesn't "grow on trees."

The comments to this entry are closed.

September 2017

Sun Mon Tue Wed Thu Fri Sat
          1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30